K. King

Selection of Resistance in Protease Inhibitor-Experienced, Human Immunodeficiency Virus Type 1-Infected Subjects Failing Lopinavir- and Ritonavir-Based Therapy: Mutation Patterns and Baseline Correlates

A. Molla, D. Kempf, H. Mo, 2005, Journal of Virology.

Effects of Acid‐Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir and Ritonavir‐Boosted Atazanavir

K. King, Y. Chiu, K. Beck, 2008, Journal of clinical pharmacology.

Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study

M. King, K. King, S. Brun, 2004, AIDS.

Substitution with Lopinavir/Ritonavir Improves Patient-Reported Outcomes Including Quality of Life in Patients Who Were Intolerant to Their Antiretroviral Therapy

K. King, S. Brun, E. Sprinz, 2006, HIV clinical trials.

Lack of Effect of Acid Reducing Agents on the Pharmacokinetics (PK) of Lopinavir/Ritonavir (LPV/r) Tablet Formulation

K. King, K. Beck, G. Hanna, 2006 .